Skip to content

Clinical trials

Aortic Valve Insufficiency trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Aortic Valve Insufficiency Country / region: Canada Clear all

14 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20072
20101
20122
20174
20191
20232
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed8
Recruiting4
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Edwards Lifesciences3
Abbott Medical Devices2
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec2
Sorin Group USA, Inc.2
Imperial College London1
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval1
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC1
McGill University Health Centre/Research Institute of the McGill University Health Centre1
Symetis SA1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Aortic Valve Insufficiency14
Aortic Valve Stenosis11
Coronary Artery Disease2
Heart Failure2
Prosthesis Failure2
Aortic Diseases1
Aortic Valve Disease1
Cardiomyopathy, Dilated1
Cardiomyopathy, Hypertrophic1
Gastroesophageal Reflux1

Trials

Showing 26 to 14 of 14. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.